G

Galmed Pharmaceuticals Ltd
D

GLMD

2.90000
USD
0.02
(0.69%)
مغلق
حجم التداول
411
الربح لكل سهم
-1
العائد الربحي
-
P/E
0
حجم السوق
4,805,277
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    0.035
    (0.20%)
    17.560 USD
    A
    AMRN
    -0.00210
    (-0.38%)
    0.55580 USD
    BGNE
    BGNE
    0
    (0.00%)
    0 USD
    C
    CTMX
    -0.00370
    (-0.44%)
    0.84340 USD
    E
    EGRX
    0
    (0%)
    0 USD
    F
    FGEN
    0.00940
    (1.62%)
    0.59010 USD
    J
    JAZZ
    -1.420
    (-1.16%)
    121.260 USD
    JNJ
    JNJ
    -0.740
    (-0.50%)
    147.060 USD
    L
    LIVN
    0.312
    (0.65%)
    48.292 USD
    M
    MYOV
    0
    (0%)
    0 USD
    N
    NBRV
    0.04000
    (2.84%)
    1.45000 USD
    R
    RIGL
    2.810
    (16.21%)
    20.140 USD
    S
    SSNC
    -0.660
    (-0.83%)
    78.470 USD
    X
    XENE
    -1.240
    (-3.12%)
    38.460 USD
    X
    XNCR
    -0.780
    (-3.90%)
    19.240 USD
    المزيد
الأخبار
المقالات

العنوان: Galmed Pharmaceuticals Ltd

القطاع: Healthcare
الصناعة: Biotechnology
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIaclinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.